Drug delivery strategies for photodynamic antimicrobial chemotherapy: From benchtop to clinical practice

C. M. Cassidy, M. M. Tunney, Paul McCarron, R. F. Donnelly

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Light and photosensitizer-mediated killing of many pathogens, termed photodynamic antimicrobial chemotherapy (PACT), has been extensively investigated in vitro. A wide range of organisms from the Gram-positive Staphylococcus aureus to the Gram-negative Pseudomonas aeruginosa have been proven to be susceptible to PACT. Multidrug-resistant strains are just as susceptible to this treatment as their naive counterparts. Both enveloped and non-enveloped viruses have demonstrated susceptibility in vitro, in addition to fungi and protozoa. Significantly, however, no clinical treatments based on PACT are currently licensed. This paper provides a comprehensive review of work carried out to date on delivery of photosensitizers for use in PACT, including topical, intranasal and oral/buccal delivery, as well as targeted delivery. We have also reviewed photo-antimicrobial surfaces. It is hoped that, through a rational approach to formulation design and subsequent success in small-scale clinical trials, more widespread use will be made of PACT in the clinic, to the benefit of patients worldwide. (C) 2009 Elsevier B.V. All rights reserved.
LanguageEnglish
Pages71-80
JournalJOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
Volume95
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

chemotherapy
delivery
drugs
Drug Therapy
Photosensitizing Agents
Pharmaceutical Preparations
protozoa
pseudomonas
staphylococcus
pathogens
fungi
Cheek
viruses
organisms
Pseudomonas aeruginosa
Staphylococcus aureus
Fungi
Clinical Trials
Viruses
magnetic permeability

Cite this

@article{69296c5c24b942d0954ff79643c94499,
title = "Drug delivery strategies for photodynamic antimicrobial chemotherapy: From benchtop to clinical practice",
abstract = "Light and photosensitizer-mediated killing of many pathogens, termed photodynamic antimicrobial chemotherapy (PACT), has been extensively investigated in vitro. A wide range of organisms from the Gram-positive Staphylococcus aureus to the Gram-negative Pseudomonas aeruginosa have been proven to be susceptible to PACT. Multidrug-resistant strains are just as susceptible to this treatment as their naive counterparts. Both enveloped and non-enveloped viruses have demonstrated susceptibility in vitro, in addition to fungi and protozoa. Significantly, however, no clinical treatments based on PACT are currently licensed. This paper provides a comprehensive review of work carried out to date on delivery of photosensitizers for use in PACT, including topical, intranasal and oral/buccal delivery, as well as targeted delivery. We have also reviewed photo-antimicrobial surfaces. It is hoped that, through a rational approach to formulation design and subsequent success in small-scale clinical trials, more widespread use will be made of PACT in the clinic, to the benefit of patients worldwide. (C) 2009 Elsevier B.V. All rights reserved.",
author = "Cassidy, {C. M.} and Tunney, {M. M.} and Paul McCarron and Donnelly, {R. F.}",
note = "PT: J; TC: 1",
year = "2009",
doi = "10.1016/j.photobiol.2009.01.005",
language = "English",
volume = "95",
pages = "71--80",
journal = "Journal of Photochemistry and Photobiology B: Biology",
issn = "1011-1344",
publisher = "Elsevier",
number = "2",

}

Drug delivery strategies for photodynamic antimicrobial chemotherapy: From benchtop to clinical practice. / Cassidy, C. M.; Tunney, M. M.; McCarron, Paul; Donnelly, R. F.

In: JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY, Vol. 95, No. 2, 2009, p. 71-80.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Drug delivery strategies for photodynamic antimicrobial chemotherapy: From benchtop to clinical practice

AU - Cassidy, C. M.

AU - Tunney, M. M.

AU - McCarron, Paul

AU - Donnelly, R. F.

N1 - PT: J; TC: 1

PY - 2009

Y1 - 2009

N2 - Light and photosensitizer-mediated killing of many pathogens, termed photodynamic antimicrobial chemotherapy (PACT), has been extensively investigated in vitro. A wide range of organisms from the Gram-positive Staphylococcus aureus to the Gram-negative Pseudomonas aeruginosa have been proven to be susceptible to PACT. Multidrug-resistant strains are just as susceptible to this treatment as their naive counterparts. Both enveloped and non-enveloped viruses have demonstrated susceptibility in vitro, in addition to fungi and protozoa. Significantly, however, no clinical treatments based on PACT are currently licensed. This paper provides a comprehensive review of work carried out to date on delivery of photosensitizers for use in PACT, including topical, intranasal and oral/buccal delivery, as well as targeted delivery. We have also reviewed photo-antimicrobial surfaces. It is hoped that, through a rational approach to formulation design and subsequent success in small-scale clinical trials, more widespread use will be made of PACT in the clinic, to the benefit of patients worldwide. (C) 2009 Elsevier B.V. All rights reserved.

AB - Light and photosensitizer-mediated killing of many pathogens, termed photodynamic antimicrobial chemotherapy (PACT), has been extensively investigated in vitro. A wide range of organisms from the Gram-positive Staphylococcus aureus to the Gram-negative Pseudomonas aeruginosa have been proven to be susceptible to PACT. Multidrug-resistant strains are just as susceptible to this treatment as their naive counterparts. Both enveloped and non-enveloped viruses have demonstrated susceptibility in vitro, in addition to fungi and protozoa. Significantly, however, no clinical treatments based on PACT are currently licensed. This paper provides a comprehensive review of work carried out to date on delivery of photosensitizers for use in PACT, including topical, intranasal and oral/buccal delivery, as well as targeted delivery. We have also reviewed photo-antimicrobial surfaces. It is hoped that, through a rational approach to formulation design and subsequent success in small-scale clinical trials, more widespread use will be made of PACT in the clinic, to the benefit of patients worldwide. (C) 2009 Elsevier B.V. All rights reserved.

U2 - 10.1016/j.photobiol.2009.01.005

DO - 10.1016/j.photobiol.2009.01.005

M3 - Article

VL - 95

SP - 71

EP - 80

JO - Journal of Photochemistry and Photobiology B: Biology

T2 - Journal of Photochemistry and Photobiology B: Biology

JF - Journal of Photochemistry and Photobiology B: Biology

SN - 1011-1344

IS - 2

ER -